

Diversity in oncology clinical trials: current landscape for industry-sponsored clinical trials in Asia?

Singh et al.

ORIGINAL RESEARCH

Authors:

1. Dany Habr¹ (ORCID ID: 0000-0002-3361-6309)
2. Manmohan Singh² (ORCID ID: 0000-0002-9175-8559)
3. Roberto Uehara³ (ORCID ID: 0000-0003-3888-9477)

¹Medical affairs, Oncology, Pfizer Oncology, Pfizer Inc, New York City, New York, USA

²Regional Medical Affairs, Pfizer Corporation Hong Kong Limited, Hong Kong, Hong Kong

³Medical affairs, Oncology, Pfizer Oncology - Emerging Markets, Pfizer Inc, New York City, New York, USA

Corresponding author:

Dr Manmohan Singh, MD

Regional Oncology Medical Lead, Emerging Asia,

Pfizer Corporation Hong Kong Ltd,

21st Floor, Kerry Center, 683 King's Road, Quarry Bay, Hong Kong

Tel: +852 2406 3946, Fax: +852 2918 1220,

Email: Manmohan.Singh@Pfizer.com

Supplementary Figure 1. Selection of industry-sponsored oncology clinical trials for final analysis

Final study sample

Overall sample = 912

All Phase 2 and 3 interventional trials studying a drug, or biologic for cancer treatment from [Clinicaltrials.gov](https://clinicaltrials.gov) with any funding by industry with start date between January 1, 2018, and December 31, 2022 (last 5 years).*


*Including Recruiting, Not yet recruiting, Active, not recruiting, Completed, Enrolling by invitation, Suspended, Terminated, Unknown status

Exclusion criteria

✖ Trials without information on the study location, **n=18**

Final study sample (for data analysis) = 894 trials

Trials with sites in Asia only (A)	Trials with sites in Asia and other countries outside (Ao)	Trials with sites in Asia (A+Ao)	Trials without sites in Asia
n=204 (22.82%)	n=211 (23.60%)	n=415 (46.42%)	n=479 (53.58%)



Supplementary Table 1. A breakdown for Industry-sponsored cancer trials with sites in Asia: trials with sites in Asia only and trials with sites in Asia and other countries outside Asia*

Trial characteristics	Trials with sites in Asia only (n=204)	Trials with sites in Asia and other countries outside Asia (n=211)	Trials with sites in Asia (n=415)
Number of sites, Median (Q1, Q3)	1.0 (1.0, 3.0)	73.0 (34.0, 168.0)	17.0 (1.0, 74.5)
Target enrolment, Median (Q1, Q3)	67.0 (30.8, 189.5)	350.0 (135.5, 699.5)	144.0 (54.0, 480.0)
Funding type, n (%)			
Industry as the sole funder	139 (68.14)	195 (92.42)	334 (80.48)
Industry with other funders	65 (31.86)	16 (7.58)	81 (19.52)
Trial phase, n (%)			
Phase 2	154 (75.49)	105 (49.76)	259 (62.41)
Phase 3	51 (25.00)	114 (54.03)	165 (39.76)
Gender, n (%)			
All	162 (79.41)	185 (87.68)	347 (83.61)
Female	36 (17.65)	20 (9.48)	56 (13.49)
Male	6 (2.94)	6 (2.84)	12 (2.89)
Study population, n (%)			
Adults (18-64 years)	203 (99.51)	210 (99.53)	413 (99.52)
Older adults (≥ 65 years)	176 (86.27)	203 (96.21)	379 (91.33)
Pediatric (birth–17 years)	33 (16.18)	17 (8.06)	50 (12.05)
Trial design, n (%)			
Non-Randomised	129 (63.24)	57 (27.01)	186 (44.82)
Randomised	75 (36.76)	154 (72.99)	229 (55.18)

Supplementary Table 2. Top 10 Asian countries according to number of trials having at least one site in Asia, n (%)

Country	Trials with sites in Asia only (n=204)	Trials with sites in Asia and other countries outside Asia (n=211)	Trials with sites in Asia (n=415)
China	165 (80.88)	69 (32.70)	234 (56.39)
Republic Of Korea	12 (5.88)	119 (56.40)	131 (31.57)
Japan	10 (4.90)	95 (45.02)	105 (25.30)
Israel	1 (0.49)	96 (45.50)	97 (23.37)
Taiwan	9 (4.41)	84 (39.81)	93 (22.41)
Turkey	0 (0.00)	67 (31.75)	67 (16.14)
Hong Kong	0 (0.00)	33 (15.64)	33 (7.95)
Singapore	1 (0.49)	30 (14.22)	31 (7.47)
Thailand	0 (0.00)	18 (8.53)	18 (4.34)
Malaysia	0 (0.00)	16 (7.58)	16 (3.86)

Supplementary Table 3. Year-on-year growth in industry-sponsored cancer clinical trials by the geographic locations of the recruiting sites

Geographic location of trials	2018 N (CAGR %)	2019 N (CAGR %)	2020 N (CAGR %)	2021 N (CAGR %)	2022 N (CAGR %)
Trials with Sites in Asia only	46 (NA)	45 (-1.09)	34 (-9.59)	46 (0.00)	33 (-6.43)
Trials with sites in Asia and other countries outside Asia	46 (NA)	42 (-4.45)	40 (-4.55)	49 (1.59)	34 (-5.87)
Trials with sites in Asia	92 (NA)	87 (-2.76)	74 (-7.00)	95 (0.81)	67 (-6.15)
Trials without sites in Asia	112 (NA)	94 (-8.39)	91 (-6.69)	93 (-4.54)	89 (-4.49)

CAGR, Compound Annual Growth Rate